Skipping lymph node removal for melanoma with good treatment response
Part of Cancer, Skin clinical trials.
This trial tests whether patients with stage 3 melanoma that shrinks significantly after initial immunotherapy can safely avoid having all their lymph nodes surgically removed. Instead, only the main affected node is removed for testing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 16 years or older
- You have stage 3 melanoma that has spread to at least one lymph node that can be felt or seen on scans
- You are eligible to receive immunotherapy (ipilimumab and nivolumab) before surgery
- The affected lymph node can be marked for identification
- You have not had prior immunotherapy or targeted therapy for melanoma
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if injecting two immunotherapy drugs (ipilimumab and nivolumab) just under the skin can help prevent high-risk stage II melanoma from spreading. It is for people who have recently had a thick melanoma removed and have not yet had a sentinel node biopsy.
This trial studies nivolumab, an immune medicine, for melanoma that has spread to the skin along a limb (called in-transit metastases). It’s given after a procedure that delivers higher treatment levels to the affected limb, with the goal of shrinking the melanoma and improving outcomes.
This trial tests if a specific type of lymph node surgery, combined with a short course of immunotherapy (medicines that help your immune system fight cancer), works better for melanoma that has spread to nearby lymph nodes. It's for people whose melanoma can be removed and who are healthy enough for treatment.
This trial tests whether removing a clinically involved lymph node basin (via a specific lymph node excision surgery) after certain melanoma findings is helpful. It mainly aims to see effects on outcomes and on arm/leg swelling (lymphedema) after surgery.
This trial tests whether a combination of two immunotherapy drugs (nivolumab and relatlimab) can clear tiny amounts of cancer cells that remain after surgery in people with high-risk melanoma. It aims to prevent the cancer from coming back.
This trial tests a combination of two drugs (LTX-315 and pembrolizumab) given before surgery to shrink melanoma that is stage III or IV (M1a) and can be removed. The goal is to see if this approach works better than surgery alone.
Hear when a new Melanoma (Skin) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.